KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Other Non-Current Liabilities (2016 - 2025)

Cvs Health (CVS) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $4.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 12.04% year-over-year to $4.8 billion, compared with a TTM value of $4.8 billion through Dec 2025, down 12.04%, and an annual FY2025 reading of $4.8 billion, down 12.04% over the prior year.
  • Other Non-Current Liabilities was $4.8 billion for Q4 2025 at Cvs Health, roughly flat from $4.8 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.8 billion in Q3 2022 and bottomed at $1.9 billion in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $4.7 billion, with a median of $5.4 billion recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities decreased 19.01% in 2021, then surged 253.47% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $1.9 billion in 2021, then soared by 253.47% to $6.7 billion in 2022, then dropped by 7.71% to $6.2 billion in 2023, then fell by 12.56% to $5.4 billion in 2024, then fell by 12.04% to $4.8 billion in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CVS at $4.8 billion in Q4 2025, $4.8 billion in Q3 2025, and $4.8 billion in Q2 2025.